Last reviewed · How we verify
Palmitoylethanolamide — Competitive Intelligence Brief
phase 3
Cannabinoid receptor 2, Cannabinoid receptor 1, G-protein coupled receptor 55
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Palmitoylethanolamide (PALMIDROL). Palmitoylethanolamide works by binding to the G-protein coupled receptor 55, which helps regulate inflammation and pain.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Palmitoylethanolamide TARGET | PALMIDROL | phase 3 | Cannabinoid receptor 2, Cannabinoid receptor 1, G-protein coupled receptor 55 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Palmitoylethanolamide CI watch — RSS
- Palmitoylethanolamide CI watch — Atom
- Palmitoylethanolamide CI watch — JSON
- Palmitoylethanolamide alone — RSS
Cite this brief
Drug Landscape (2026). Palmitoylethanolamide — Competitive Intelligence Brief. https://druglandscape.com/ci/palmidrol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing